Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

US9867830B2 · kind B2 · utility

Assignees

• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · US
• COOPER HEALTH SYSTEM · US
• SRI International · US

Inventors

• Irving W. Wainer · Washington, US
• Ruin Moaddel · Bel Air, US
• Michel Bernier · Pikesville, US
• Carlos A. Zarate · Rockville, US
• MARC C. TORJMAN · Southampton, US
• Michael E. Goldberg · Ivyland, US
• Mary J. Tanga · Menlo Park, US

Key dates

• Filing date: Nov 2, 2016
• Grant date: Jan 16, 2018
• Expiry date: Nov 2, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.(2R,6R)-hydroxynorketamineThe disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.